Plain-English translation of NCT07679893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing nintedanib, a medication delivered as a dry powder you inhale directly into your lungs, to see if it can help treat idiopathic pulmonary fibrosis (IPF)—a serious condition where lung tissue becomes scarred and stiff, making it harder to breathe. Researchers want to find the safest and most effective dose of this medication and understand how well it works compared to a placebo (inactive powder). You would be randomly assigned to receive either the medication at one of two dose levels or placebo for 12 weeks, and then everyone continues with the active treatment for another 24 weeks.
Idiopathic pulmonary fibrosis is a progressive disease with limited treatment options, and patients need new approaches to slow the scarring and preserve lung function. This trial explores whether delivering nintedanib directly to the lungs as an inhaled powder might be more effective and better tolerated than other forms of the same drug.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic regularly for 12 weeks while taking either the medication or placebo as an inhaled dry powder four times a day (or twice a day, depending on your assigned group). The study team will monitor your lung function with breathing tests, check your blood work, and watch for any side effects. After 12 weeks, all participants receive the active medication for another 24 weeks. Throughout the trial, you'll need to attend multiple clinic visits and be willing to perform spirometry tests (breathing exercises that measure how well your lungs work).
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Canada